Hexarelin
Growth Hormone SecretagogueresearchAlso known as: Examorelin, HEX, MF-6003
A synthetic hexapeptide growth hormone secretagogue that potently stimulates GH release through the ghrelin receptor, with additional cardioprotective properties.
Overview
Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) composed of six amino acids. It is one of the most potent GHRPs available, stimulating growth hormone release by activating the ghrelin/GHS-R1a receptor in the pituitary gland. Unlike many other GHRPs, hexarelin has demonstrated significant cardioprotective effects independent of its GH-releasing properties, including protection against ischemia-reperfusion injury and improvement of cardiac function. Hexarelin does not significantly stimulate appetite compared to other ghrelin mimetics, making it useful for those seeking GH benefits without increased hunger. However, it is notable for developing desensitization relatively quickly compared to other GHRPs, typically requiring cycling protocols.
Mechanism of Action
Hexarelin binds to the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs, triggering a signaling cascade that results in robust GH release. It also acts through GHS-R1a-independent pathways, particularly in cardiac tissue, where it activates protective signaling via the CD36 scavenger receptor. Hexarelin stimulates GH release through both hypothalamic GHRH amplification and direct pituitary action. Its cardioprotective effects involve activation of the PI3K/Akt pathway and reduction of oxidative stress in cardiomyocytes.
Molecular Formula
C47H58N12O6
Molecular Weight
887.04 g/mol
Sequence
His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
Dosage Protocols
Dose Range
100mcg – 200mcg
Frequency
2-3 times daily
Route
subcutaneous
Cycle Length
8-12 weeks (with 4 week breaks)
Administer on an empty stomach. Prone to desensitization; cycling is essential. Most effective when combined with a GHRH peptide like CJC-1295.
Source: Clinical trials and community protocols
Side Effects
| Effect | Severity |
|---|---|
| Increased cortisol | mild |
| Increased prolactin | mild |
| Water retention | mild |
| Injection site irritation | mild |
| Desensitization | moderate |
| Numbness or tingling | mild |
Pros & Cons
One of the most potent GHRPs for stimulating growth hormone release
Unique cardioprotective properties independent of GH release, beneficial for heart health
Does not significantly increase appetite unlike GHRP-6 and other ghrelin mimetics
Well-studied in human clinical trials with established safety and efficacy data
Develops desensitization faster than other GHRPs, requiring strict cycling protocols
Raises cortisol and prolactin more than ipamorelin or GHRP-2
Not FDA-approved; available only as a research chemical
Banned by WADA for competitive athletes
Research Studies
Legal Status
Not FDA-approved. Available as a research chemical. Banned by WADA for competitive athletes. Investigated in clinical trials for GH deficiency and cardiac conditions.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
Ipamorelin
A highly selective growth hormone-releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it the cleanest GHRP available.